应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
03880 泰德医药
交易中 07-29 15:59:18
34.150
+0.450
+1.34%
最高
34.300
最低
32.900
成交量
27.53万
今开
33.800
昨收
33.700
日振幅
4.15%
总市值
48.49亿
流通市值
25.13亿
总股本
1.42亿
成交额
922.80万
换手率
0.37%
流通股本
7,360万
市净率
13.91
ROE
20.67%
每股收益
0.00
52周最高
40.100
52周最低
28.100
市盈率
--
股息
0.00
股息收益率
0.00
ROA
5.25%
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
泰德医药07月28日遭主力抛售94.0万元
市场透视 · 07-28 08:15
泰德医药07月28日遭主力抛售94.0万元
泰德医药(03880)获中国证监会受理H股全流通计划的申请
智通财经 · 07-27 10:30
泰德医药(03880)获中国证监会受理H股全流通计划的申请
泰德医药07月24日获主力加仓46.4万元
市场透视 · 07-24
泰德医药07月24日获主力加仓46.4万元
泰德医药07月23日主力净流入52.1万元 散户资金抛售
市场透视 · 07-23
泰德医药07月23日主力净流入52.1万元 散户资金抛售
港股IPO上半年表现亮眼,融资额荣登全球第一!下半年IPO机会抢先看
老虎资讯综合 · 07-23
港股IPO上半年表现亮眼,融资额荣登全球第一!下半年IPO机会抢先看
泰德医药07月21日遭主力抛售81.4万元
市场透视 · 07-21
泰德医药07月21日遭主力抛售81.4万元
泰德医药07月17日主力净流出46.6万元 散户资金买入
市场透视 · 07-17
泰德医药07月17日主力净流出46.6万元 散户资金买入
泰德医药07月15日主力净流出96.4万元 散户资金买入
市场透视 · 07-15
泰德医药07月15日主力净流出96.4万元 散户资金买入
泰德医药07月11日获主力加仓109.5万元
市场透视 · 07-11
泰德医药07月11日获主力加仓109.5万元
近期国内融资|泰德医药、拨康视云港交所上市
药菓 · 07-07
近期国内融资|泰德医药、拨康视云港交所上市
泰德医药:多肽CRDMO领域龙头在港交所上市有望打开更大成长空间
动脉网 · 07-01
泰德医药:多肽CRDMO领域龙头在港交所上市有望打开更大成长空间
风口上的卖铲人,全球第三大多肽CRDMO港股上市
动脉网 · 07-01
风口上的卖铲人,全球第三大多肽CRDMO港股上市
异动解读 | 泰德医药上市首日盘中大涨5.23%,全球第三大多肽CRDMO前景看好
异动解读 · 06-30
异动解读 | 泰德医药上市首日盘中大涨5.23%,全球第三大多肽CRDMO前景看好
异动解读 | 泰德医药首日挂牌大涨5.23%,全球第三大多肽CRDMO受市场追捧
异动解读 · 06-30
异动解读 | 泰德医药首日挂牌大涨5.23%,全球第三大多肽CRDMO受市场追捧
一家CRDMO港股上市,CRO项目1217个
生物药大时代 · 06-30
一家CRDMO港股上市,CRO项目1217个
异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷
异动解读 · 06-30
异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷
新股定价|泰德医药公开发售超购300倍,一手中签50%
老虎资讯综合 · 06-29
新股定价|泰德医药公开发售超购300倍,一手中签50%
新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元
智通财经 · 06-27
新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元
老虎暗盘|泰德医药盘初拉升,为“全球第三大多肽CRDMO”
老虎资讯综合 · 06-27
老虎暗盘|泰德医药盘初拉升,为“全球第三大多肽CRDMO”
多肽CRDMO新贵赴港IPO
药智网 · 06-27
多肽CRDMO新贵赴港IPO
加载更多
公司概况
公司名称:
泰德医药
所属市场:
SEHK
上市日期:
2025-06-30
主营业务:
泰德医药(浙江)股份有限公司是一家主要从事多肽的合约研究、开发和生产的中国公司。该公司主要提供合约研究机构(CRO)服务,即多肽新化学实体(NCE)发现合成、合约开发及生产机构(CDMO)服务即多肽化学、制造及控制(CMC)开发以及商业化生产。该公司的服务主要专注于向客户提供活性药物成分(APIs),而非药品。该公司也为客户提供多肽类药物开发、生产、CMC申报支持服务。该公司主要在国内市场和海外市场开展业务。
发行价格:
30.600
{"stockData":{"symbol":"03880","market":"HK","secType":"STK","nameCN":"泰德医药","latestPrice":34.15,"timestamp":1753775949248,"preClose":33.7,"halted":0,"volume":275300,"delay":0,"floatShares":73598888,"shares":142000000,"eps":0,"marketStatus":"交易中","change":0.45,"latestTime":"07-29 15:59:15","open":33.8,"high":34.3,"low":32.9,"amount":9228020,"amplitude":0.041543,"askPrice":34.15,"askSize":1800,"bidPrice":34,"bidSize":2400,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1753776600000},"marketStatusCode":2,"adr":0,"listingDate":1751212800000,"exchange":"SEHK","adjPreClose":33.7,"openAndCloseTimeList":[[1753752600000,1753761600000],[1753765200000,1753776000000]],"volumeRatio":0.561127,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/03880","defaultTab":"news","newsList":[{"id":"2554716397","title":"泰德医药07月28日遭主力抛售94.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2554716397","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554716397?lang=zh_cn&edition=full","pubTime":"2025-07-28 16:15","pubTimestamp":1753690516,"startTime":"0","endTime":"0","summary":"07月28日, 泰德医药股价跌0.59%,报收33.70元,成交金额1196.2万元,换手率0.49%,振幅6.49%,量比0.78。泰德医药今日主力资金净流出94.0万元,上一交易日主力净流出100.2万元。|07月28日主力加仓幅度排名||#|股票简称|主力净额占比|#|宏基集团控股|3.17%|#|嘉鼎国际集团|3.15%|#|火山邑动国际控股|2.82%|#|...|...|#2457|泰德医药|-0.04%|(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728164751a4675d23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728164751a4675d23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2554483327","title":"泰德医药(03880)获中国证监会受理H股全流通计划的申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2554483327","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554483327?lang=zh_cn&edition=full","pubTime":"2025-07-27 18:30","pubTimestamp":1753612226,"startTime":"0","endTime":"0","summary":"智通财经APP讯,泰德医药(03880)公布,中国证券监督管理委员会已受理该公司代表公司特定股东向中国证监会提交的关于建议实施H股全流通的申请。根据相关申请文件,公司已申请将公司该等股东所持有每股面值为人民币1.0元的 68,201,112股已发行非上市股份转换为每股面值人民币1.0元的 H股,有关股份占公司于本公告日期已发行股本总额约 48.10%。本次H股全流通完成后,参与本次H股全流通的所有持有非上市股份的股东仍须按照上市规则及适用法律法规的要求,履行股份锁定承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1322323.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880"],"gpt_icon":0},{"id":"2553202494","title":"泰德医药07月24日获主力加仓46.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553202494","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553202494?lang=zh_cn&edition=full","pubTime":"2025-07-24 16:15","pubTimestamp":1753344954,"startTime":"0","endTime":"0","summary":"07月24日, 泰德医药股价涨1.19%,报收34.00元,成交金额5451.1万元,换手率2.32%,振幅6.25%,量比7.46。泰德医药今日主力资金净流入46.4万元,上一交易日主力净流入52.1万元。|07月24日主力加仓幅度排名||#|股票简称|主力净额占比|#|宏基集团控股|3.27%|#|金力永磁|2.50%|#|中州证券|1.64%|#|...|...|#392|泰德医药|0.02%|(以上内容为腾讯自选股基于公开消息,由程序或算法智能生成,仅作为用户看盘参考,不作为投资建议或交易依据。股市有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724170204a460eeb6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250724170204a460eeb6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2553216000","title":"泰德医药07月23日主力净流入52.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2553216000","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553216000?lang=zh_cn&edition=full","pubTime":"2025-07-23 16:15","pubTimestamp":1753258534,"startTime":"0","endTime":"0","summary":"07月23日, 泰德医药股价涨0.30%,报收33.60元,成交金额310.5万元,换手率0.12%,振幅4.03%,量比0.31。泰德医药今日主力资金净流入52.1万元,上一交易日主力净流出0.1万元。该股近5个交易日下跌1.75%,主力资金累计净流出449.9万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入1606.4万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723165626a45e7420&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250723165626a45e7420&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"1117162350","title":"港股IPO上半年表现亮眼,融资额荣登全球第一!下半年IPO机会抢先看","url":"https://stock-news.laohu8.com/highlight/detail?id=1117162350","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117162350?lang=zh_cn&edition=full","pubTime":"2025-07-23 11:36","pubTimestamp":1753241761,"startTime":"0","endTime":"0","summary":"2025上半年港股市场势头向好,港股IPO上半年表现尤为亮眼,42宗首次公开招股发行,合共集资额逾过1,070亿港元,与去年同期相比,上市数量增长40%,融资总额飙升逾7倍。整体来看,2025年上半年港股市场凭借政策红利、资金回流与情绪修复实现强势复苏,医药、消费、A+H板块成为IPO主力;展望下半年,在巨头排队、政策持续利好的背景下,港股市场热度有望进一步延续。","market":"hk","thumbnail":"https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e2bc484766922e67d87fdb952e5532ab"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"港股IPO上半年表现亮眼,融资额荣登全球第一!下半年IPO机会抢先看","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01828","02597","06883","06168","09881","02592","02605","03288","02648","02619","02643","02590","02609","02617","02651","09678","06603","02508","02573","03880","01304","06613","02050"],"gpt_icon":0},{"id":"2553403699","title":"泰德医药07月21日遭主力抛售81.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2553403699","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553403699?lang=zh_cn&edition=full","pubTime":"2025-07-21 16:15","pubTimestamp":1753085753,"startTime":"0","endTime":"0","summary":"07月21日, 泰德医药股价跌3.02%,报收33.70元,成交金额615.5万元,换手率0.25%,振幅4.75%,量比0.27。泰德医药今日主力资金净流出81.4万元,连续3日净流出,上一交易日主力净流出373.8万元。该股近5个交易日下跌8.80%,主力资金累计净流出481.3万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入1554.4万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165954a4590072&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250721165954a4590072&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2552439366","title":"泰德医药07月17日主力净流出46.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2552439366","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552439366?lang=zh_cn&edition=full","pubTime":"2025-07-17 16:15","pubTimestamp":1752740135,"startTime":"0","endTime":"0","summary":"07月17日, 泰德医药股价跌0.58%,报收34.00元,成交金额1214.4万元,换手率0.49%,振幅7.31%,量比0.60。泰德医药今日主力资金净流出46.6万元,上一交易日主力净流入116.9万元。该股近5个交易日上涨10.93%,主力资金累计净流入935.3万元,其中1个交易日为股价下跌时净流入;近20日主力资金累计净流入2009.7万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171246a6af6a1f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250717171246a6af6a1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2551168328","title":"泰德医药07月15日主力净流出96.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2551168328","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551168328?lang=zh_cn&edition=full","pubTime":"2025-07-15 16:15","pubTimestamp":1752567310,"startTime":"0","endTime":"0","summary":"07月15日, 泰德医药股价跌3.25%,报收35.75元,成交金额2693.3万元,换手率0.98%,振幅15.16%,量比1.28。泰德医药今日主力资金净流出96.4万元,上一交易日主力净流入851.9万元。该股近5个交易日上涨14.79%,主力资金累计净流入1105.5万元,其中2个交易日为股价下跌时净流入;近20日主力资金累计净流入1939.3万元,其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715164614a6aab19e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715164614a6aab19e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2550540936","title":"泰德医药07月11日获主力加仓109.5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550540936","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550540936?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:15","pubTimestamp":1752221710,"startTime":"0","endTime":"0","summary":"07月11日, 泰德医药股价涨1.96%,报收31.25元,成交金额937.8万元,换手率0.41%,振幅3.59%,量比0.63。泰德医药今日主力资金净流入109.5万元,连续7日净流入,上一交易日主力净流入11.1万元。该股近5个交易日下跌0.95%,主力资金累计净流入1330.3万元;近20日主力资金累计净流入1183.8万元,其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711165440a6a368e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250711165440a6a368e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2549539224","title":"近期国内融资|泰德医药、拨康视云港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539224","media":"药菓","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549539224?lang=zh_cn&edition=full","pubTime":"2025-07-07 18:01","pubTimestamp":1751882490,"startTime":"0","endTime":"0","summary":"公司致力于开发新一代治疗性和诊断用抗体药物,通过自主研发的智能抗体技术,能够高效设计并生成满足临床需求的抗体,同时显著降低治疗性抗体的开发成本。禾元生物成立于2006年,以植物表达动物蛋白的方式,生产药品、药用辅料及科研试剂。这也是重启科创板第五套上市标准后,首家按此标准成功过会的IPO企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191409a43bbb36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191409a43bbb36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","03880"],"gpt_icon":1},{"id":"2548025873","title":"泰德医药:多肽CRDMO领域龙头在港交所上市有望打开更大成长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2548025873","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548025873?lang=zh_cn&edition=full","pubTime":"2025-07-01 10:44","pubTimestamp":1751337840,"startTime":"0","endTime":"0","summary":"泰德医药,多肽CRDMO领域龙头,6月30日在港交所上市,计划扩大在美国和中国的设施,以显著提升服务能力和产能,迎接更大成长空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701110544953200a3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701110544953200a3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":0},{"id":"2548044879","title":"风口上的卖铲人,全球第三大多肽CRDMO港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548044879","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548044879?lang=zh_cn&edition=full","pubTime":"2025-07-01 08:04","pubTimestamp":1751328243,"startTime":"0","endTime":"0","summary":"6月30日,专注于多肽CRDMO的泰德医药成功登陆港交所。经过多年发展,泰德医药已经成为全球多肽CRDMO领域的重要玩家。02千亿多肽CRDMO赛道迎来黄金发展期GLP-1的爆火显著推动了全球多肽CRDMO市场的增长。对第三方服务供应商的依赖导致全球多肽CRDMO市场快速增长,按销售收入计,该市场的规模由2018年的16亿美元增加至2023年的31亿美元,复合年增长率为14.8%,预计于2032年将进一步增长至188亿美元,复合年增长率为22.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701081418a4c78e8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250701081418a4c78e8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880","HSCEI","HSTECH"],"gpt_icon":1},{"id":"1151587210","title":"异动解读 | 泰德医药上市首日盘中大涨5.23%,全球第三大多肽CRDMO前景看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1151587210","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151587210?lang=zh_cn&edition=full","pubTime":"2025-06-30 13:06","pubTimestamp":1751260007,"startTime":"0","endTime":"0","summary":"6月30日,全球第三大专注于多肽的CRDMO服务商泰德医药在港交所挂牌上市。截至发稿,该股盘中大涨5.23%,引发市场关注。泰德医药此次IPO获得投资者热烈追捧,公开发售部分获301.15倍超额认购。上市首日开盘价为30.3港元,略低于发行价,但随后股价迅速拉升。分析人士认为,泰德医药股价上涨主要有以下几个原因:首先,公司是全球第三大专注于多肽的CRDMO,市场份额达1.5%,在行业中具有领先地位。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"1170125532","title":"异动解读 | 泰德医药首日挂牌大涨5.23%,全球第三大多肽CRDMO受市场追捧","url":"https://stock-news.laohu8.com/highlight/detail?id=1170125532","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170125532?lang=zh_cn&edition=full","pubTime":"2025-06-30 13:06","pubTimestamp":1751259991,"startTime":"0","endTime":"0","summary":"6月30日,泰德医药在港交所正式挂牌上市,盘中股价大涨5.23%。截至下午1点04分,泰德医药报32.2港元,总市值达45.7亿港元。分析人士认为,泰德医药股价的强势表现反映了投资者对公司在快速增长的多肽CRDMO市场中的领先地位的认可,以及对其未来在GLP-1等热门领域发展潜力的看好。随着全球多肽药物市场的持续扩张,泰德医药有望受益于行业增长红利,进一步巩固其市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"2547566060","title":"一家CRDMO港股上市,CRO项目1217个","url":"https://stock-news.laohu8.com/highlight/detail?id=2547566060","media":"生物药大时代","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547566060?lang=zh_cn&edition=full","pubTime":"2025-06-30 12:32","pubTimestamp":1751257920,"startTime":"0","endTime":"0","summary":"泰德医药发售价为每股H股30.60港元,市值43.49亿港元。全球多肽CRDMO市场约有150名多肽CRDMO服务供应商。其专注于多肽的合约研究、开发及生产机构,是全球第三大多肽CRDMO。截至2024年12月31日,泰德医药拥有1217个在研CRO项目、332个在研CDMO项目。2024年,CDMO服务贡献3.3亿元收入,占比74.6%,美国市场营收占比55%,远超内地市场的21.4%。目前,泰德医药正推进与7位客户的9个NCE GLP-1项目开发,涵盖临床前至临床阶段。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630130025a7253d32&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630130025a7253d32&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HSCEI","03880","HSTECH"],"gpt_icon":1},{"id":"1133551242","title":"异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷","url":"https://stock-news.laohu8.com/highlight/detail?id=1133551242","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133551242?lang=zh_cn&edition=full","pubTime":"2025-06-30 09:36","pubTimestamp":1751247406,"startTime":"0","endTime":"0","summary":"6月30日,全球第三大专注于多肽的CRDMO泰德医药在港交所主板挂牌上市,但开市后股价表现不佳。截至上午9:34,泰德医药股价大跌5.07%,显示出投资者对该新股的谨慎态度。泰德医药此次IPO发行价为每股30.60港元,共发行1680万股股份。然而,上市首日股价的下跌反映出市场情绪的快速转变。泰德医药计划将此次IPO募集的资金用于扩大在美国和中国的产能,发展寡核苷酸业务,以及在欧洲设立销售及售后服务办事处。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"异动解读 | 泰德医药首日挂牌大跌5.07%,IPO超购301倍后遇冷","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03880"],"gpt_icon":1},{"id":"1107008937","title":"新股定价|泰德医药公开发售超购300倍,一手中签50%","url":"https://stock-news.laohu8.com/highlight/detail?id=1107008937","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107008937?lang=zh_cn&edition=full","pubTime":"2025-06-30 07:54","pubTimestamp":1751241271,"startTime":"0","endTime":"0","summary":"6月30日, $泰德医药$公布配发结果,每股定价30.60港元,共发行1680万股股份,每手100股,今日正式上市。上一交易日,泰德医药暗盘低开,收涨1.8%,报31.15港元,成交额8263.13万港元,总市值44.17亿港元。公开发售阶段泰德医药获301.15倍认购,经重新分配后,公开发售的发售股份最终数目为840万股股份,占发售股份总数的约50%。泰德医药主要提供CRO服务,即多肽NCE发现合成;及CDMO服务,即多肽CMC开发以及商业化生产。","market":"us","thumbnail":"https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/fb4be1ff4aaa40ac88564f80f173158e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股定价|泰德医药公开发售超购300倍,一手中签50%","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":1},{"id":"2546974197","title":"新股暗盘 | 泰德医药(03880)暗盘盘初上涨2.12% 每手赚65港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546974197","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546974197?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:21","pubTimestamp":1751012476,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,泰德医药(03880)将于6月30日(星期一)在香港挂牌。截至发稿,暗盘交易显示报价31.25港元,较招股价30.6港元上涨2.12%,每手100股,不计手续费,每手赚65港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1310798.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880"],"gpt_icon":0},{"id":"1169056197","title":"老虎暗盘|泰德医药盘初拉升,为“全球第三大多肽CRDMO”","url":"https://stock-news.laohu8.com/highlight/detail?id=1169056197","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169056197?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:17","pubTimestamp":1751012226,"startTime":"0","endTime":"0","summary":"有望受益于“减肥神药”行情。","market":"hk","thumbnail":"https://static.tigerbbs.com/94a20e74d3a441172ddc7ee6bc0c81f2","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/94a20e74d3a441172ddc7ee6bc0c81f2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03880"],"gpt_icon":0},{"id":"2546760566","title":"多肽CRDMO新贵赴港IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2546760566","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546760566?lang=zh_cn&edition=full","pubTime":"2025-06-27 11:56","pubTimestamp":1750996582,"startTime":"0","endTime":"0","summary":"6月的港股创新药市场再掀波澜——继核药龙头先通医药递交上市申请后,专注于多肽领域的CRDMO企业泰德医药于6月20日正式开启招股,预计6月30日登陆港交所主板。这家全球第三大多肽CRDMO企业的IPO进程,不仅标志着中国医药外包产业在细分领域的突破,更折射出多肽药物黄金赛道的资本热度。千亿赛道的黄金驱动力泰德医药所处的多肽CRDMO赛道,正迎来前所未有的发展机遇。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627120048a4c040d6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627120048a4c040d6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03880"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.medtideinc.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.1013},{"period":"ytd","weight":0.1013}],"compareEarnings":[{"period":"1week","weight":0.0227},{"period":"1month","weight":0.0526},{"period":"3month","weight":0.1615},{"period":"6month","weight":0.2639},{"period":"1year","weight":0.5018},{"period":"ytd","weight":0.2743}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"泰德医药(浙江)股份有限公司是一家主要从事多肽的合约研究、开发和生产的中国公司。该公司主要提供合约研究机构(CRO)服务,即多肽新化学实体(NCE)发现合成、合约开发及生产机构(CDMO)服务即多肽化学、制造及控制(CMC)开发以及商业化生产。该公司的服务主要专注于向客户提供活性药物成分(APIs),而非药品。该公司也为客户提供多肽类药物开发、生产、CMC申报支持服务。该公司主要在国内市场和海外市场开展业务。","exchange":"SEHK","name":"泰德医药","nameEN":"MEDTIDE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.4","shortVersion":"4.34.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰德医药,03880,泰德医药股票,泰德医药股票老虎,泰德医药股票老虎国际,泰德医药行情,泰德医药股票行情,泰德医药股价,泰德医药股市,泰德医药股票价格,泰德医药股票交易,泰德医药股票购买,泰德医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰德医药(03880)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰德医药(03880)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}